688566.SH
吉贝尔
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 25.41
−3.31%Year over year
Reported trailing growth
- Revenue
- +9.6%
- EBITDA
- —
- EBIT
- -1.9%
- EPS
- +13.3%
- Free cash flow
- +306.0%
- Operating cash flow
- +2.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +13.8%
- EBITDA
- +12.7%
- EBIT
- +12.9%
- Net income
- +19.1%
- EPS
- +16.4%
- Free cash flow
- +228.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026